CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-13 | Legault Pierre Director | Option exercise | +5,000 | $13.58 | $68K | 37,000 |
| 2023-01-13 | Legault Pierre Director | Sale | −5,000 | $27.00 | $135K | 32,000 |
| 2023-01-13 | Legault Pierre Director | Option exercise · Stock Options (Right to buy) | −10,000 | 0 | ||
| 2023-01-13 | Legault Pierre Director | Option exercise · Stock Options (Right to buy) | −5,000 | 0 | ||
| 2023-01-12 | Legault Pierre Director | Option exercise | +24,000 | $9.47 | $227K | 56,000 |
| 2023-01-12 | Legault Pierre Director | Sale | −24,000 | $26.74 | $642K | 32,000 |
| 2023-01-12 | Legault Pierre Director | Option exercise · Stock Options (Right to buy) | −24,000 | 0 | ||
| 2022-12-05 | Sabus Steve M Chief Commercial Officer | Grant or award · Stock Options (Right to buy) | +220,000 | $25.44 | $5.6M | 220,000 |
| 2022-12-02 | Ordentlich Peter Chief Scientific Officer | Option exercise | +17,200 | $6.38 | $110K | 17,465 |
| 2022-12-02 | Ordentlich Peter Chief Scientific Officer | Sale | −17,200 | $25.05 | $431K | 265 |
| 2022-12-02 | Ordentlich Peter Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −17,200 | 0 | ||
| 2022-12-01 | Ordentlich Peter Chief Scientific Officer | Option exercise | +3,772 | $6.35 | $24K | 4,037 |
| 2022-12-01 | Ordentlich Peter Chief Scientific Officer | Sale | −3,772 | $25.01 | $94K | 265 |
| 2022-12-01 | Ordentlich Peter Chief Scientific Officer | Option exercise | +4,028 | $6.38 | $26K | 4,293 |
| 2022-12-01 | Ordentlich Peter Chief Scientific Officer | Sale | −4,028 | $25.01 | $101K | 265 |
| 2022-12-01 | Ordentlich Peter Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −4,028 | 0 | ||
| 2022-12-01 | Ordentlich Peter Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −3,772 | 0 | ||
| 2022-10-06 | Katkin Keith Director | Option exercise | +20,782 | $7.88 | $164K | 52,782 |
| 2022-10-06 | Katkin Keith Director | Sale | −20,782 | $25.90 | $538K | 32,000 |
| 2022-10-06 | Katkin Keith Director | Option exercise | +9,117 | $8.93 | $81K | 41,117 |
Page 9 of 15 · 290 trades